Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2000

01-08-2000 | Review

Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers

Author: Rosalind A Eeles

Published in: Breast Cancer Research | Issue 4/2000

Login to get access

Abstract

The development of intervention strategies for carriers of mutations in the BRCA1 and BRCA2 genes has several considerations. The first are primary prevention and secondary prevention in unaffected carriers using medical/surgical or lifestyle strategies to prevent cancer development, or screening methods to detect cancers at an earlier stage. The options available are determined by the magnitude and age at onset, risk profile of cancer in carriers (the penetrance function of the gene) and the different cancer sites involved. The management of affected individuals who are BRCA1 and BRCA2 mutation carriers may be altered by their carrier status, because the tumour histology, efficacy of treatment and risk of subsequent cancer development is determined by the BRCA1 and BRCA2 germline status. Carriers of BRCA1 and BRCA2 mutations are relatively rare, so the strategies for management should be determined by international multicentre studies.
Literature
1.
Easton D, Peto J: The contribution of inherited predisposition to cancer incidence. Cancer Surveys. 1990, 9: 395-416.PubMed
2.
Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the Cancer and Steroid Hormone study. Am J Hum Genet. 1991, 48: 232-242.PubMedPubMedCentral
3.
Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium : Breast and ovarian cancer incidence in BRCA 1 carriers. Am J Hum Genet. 1995, 56: 265-271.CrossRefPubMedPubMedCentral
4.
Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA 1. Science. 1994, 266: 66-71., This paper describes the cloning of the BRCA1 geneCrossRefPubMed
5.
Wooster R, Bignell G, Lancaster J, et al: Identification of a breast cancer gene, BRCA2. Nature . 1995, 378: 789-791. 10.1038/378789a0., This paper describes the cloning of the BRCA2 geneCrossRefPubMed
6.
Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA-1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995, 57: 1457-1462.PubMedPubMedCentral
7.
Ford D, Easton DF, Stratton MR, et al: Genetic heterogeneity and penetrance analysis of the BRCA 1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749., This paper describes the proportion of high-risk families due to BRCA1 and BRCA2 and their phenotypic characteristics and is used by cancer geneticists when quoting penetrance figures for the high-risk familiesCrossRefPubMedPubMedCentral
8.
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risks of cancer in BRCA 1-mutation carriers. Lancet. 1994, 343: 692-695. 10.1016/S0140-6736(94)91578-4., This is the seminal paper outlining the risks of other cancers, apart from breast cancer in BRCA1 carriersCrossRefPubMed
9.
Phelan CM, Lancaster JM, Tonin P, et al: Mutation analysis of the BRCA 2 gene in 49 site-specific breast cancer families. Nature Genet. 1996, 13: 120-122.CrossRefPubMed
10.
Breast Cancer Linkage Consortium: Carrier risks in BRCA 2 mutation carriers. J Natl Cancer Inst. 1999, 91: 1310-1316. 10.1093/jnci/91.15.1310., This is the seminal paper outlining the risks of other cancers, apart from breast cancer in BRCA2 carriersCrossRef
11.
Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA 1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997, 336: 1401-1408. 10.1056/NEJM199705153362001.CrossRefPubMed
12.
Thorlacius S, Struewing JP, Hartge P, et al: Population-based study of risk of breast cancer in carriers of BRCA 2 mutation. Lancet. 1998, 352: 1337-1339. 10.1016/S0140-6736(98)03300-5.CrossRefPubMed
13.
Gayther SA, Warren W, Mazoyer S, et al: Germline mutations of the BRCA 1 gene in breast/ovarian cancer families: evidence for a genotype/phenotype correlation. Nature Genet. 1995, 11: 428-433.CrossRefPubMed
14.
Eeles R, Kaduri L: BRCA 1/2 carriers and endocrine risk modifiers. Endocrine-Related Cancer. 1999, 6: 521-528.CrossRefPubMed
15.
Shattuck-Eidens D, McClure M, Simard J, et al: A collaborative survey of 80 mutations in the BRCA 1 breast and ovarian cancer susceptibility gene. JAMA. 1995, 273: 535-541. 10.1001/jama.273.7.535.CrossRefPubMed
16.
Shattuck-Eidens D, Oliphant A, McClure M, et al: BRCA 1 sequence analysis in women at high risk for susceptibility mutations. JAMA. 1997, 278: 1242-1250. 10.1001/jama.278.15.1242.CrossRefPubMed
17.
18.
Struewing JP, Abeliovich D, Peretz T, et al: The carrier frequency of the BRCA 1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet. 1995, 11: 198-200.CrossRefPubMed
19.
Neuhausen S, Gilewski T, Norton L, et al: Recurrent BRCA 2 617delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet. 1996, 13: 126-128.CrossRefPubMed
20.
Oddoux C, Struewing JP, Clayton CM, et al: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genet . 1996, 14: 188-190.CrossRefPubMed
21.
Offit K, Gilewski T, McGuire P, et al: Germline BRCA 1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996, 347: 1643-1645. 10.1016/S0140-6736(96)91484-1.CrossRefPubMed
22.
Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA 1 and BRCA 2. Nature Genet. 1996, 14: 185-187., This paper gives results for the frequency of BRCA1 and BRCA2 mutations in Ashkenazi familiesCrossRefPubMed
23.
Tonin P, Weber B, Offit K, et al: A high frequency of BRCA 1 and BRCA 2 mutations in 222 Ashkenazi Jewish breast cancer families. Nature Med. 1996, 2: 1179-1183.CrossRefPubMed
24.
Craufurd D, Tyler A: Predictive testing for Huntington's disease: protocol of the UK Huntington's Prediction Consortium. J Med Genet. 1992, 29: 915-918.CrossRefPubMedPubMedCentral
25.
Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA: BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996, 334: 137-142. 10.1056/NEJM199601183340301.CrossRefPubMed
26.
Chamberlain J: Screening for breast cancer in high-risk populations. In: Genetic Predisposition to Cancer. Edited by Eeles R, Ponder B, Easton D, Horwich A. UK: Chapman and Hall;. 1996
27.
Eccles DM, Evans DGR, Mackay J, et al: Guidelines for a genetic risk-based approach to advising women with a family history of breast cancer. J Med Genet. 2000, 37: 203-209. 10.1136/jmg.37.3.203.CrossRefPubMedPubMedCentral
28.
Lalloo F, Boggis CR, Evans DG, Shenton A, Threlfall AG, Howell A: Screening by mammography, women with a family history of breast cancer. Eur J Cancer. 1998, 34: 937-940. 10.1016/S0959-8049(98)00005-7.CrossRefPubMed
29.
Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H: Mammographic screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer. 1997, 75: 762-766.CrossRefPubMedPubMedCentral
30.
Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S: Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiat Res. 1994, 138: 209-223.CrossRefPubMed
31.
Kote-Jarai Z, Eeles RA: BRCA1, BRCA2 and their possible function in DNA damage response. Br J Cancer. 1999, 81: 1099-1102. 10.1038/sj.bjc.6690814., This review summarises the evidence that BRCA1 and BRCA2 are involved in the DNA damage responseCrossRefPubMedPubMedCentral
32.
Peacock J, McMillan T, Eeles R, et al: Radio-sensitivity of patients carrying defects in the BRCA1 gene. Lancet . 2000,
33.
Locker AP, Caseldine J, Mitchell AK, Blamey RW, Roebuck EJ, Elston CW: Results from a seven-year programme of breast self-examination in 89,010 women. Br J Cancer. 1989, 60: 401-405.CrossRefPubMedPubMedCentral
34.
35.
Lakhani S, Sloane JP, Gusterson BA, et al: A detailed analysis of the morphological features associated with breast cancer in patients harbouring mutations in BRCA 1 and BRCA 2 predisposition genes. J Natl Cancer Inst. 1999, 90: 1138-1145. 10.1093/jnci/90.15.1138., This paper showed that the pathological features of breast cancers occurring in BRCA1 carriers are different from those in BRCA2 carriers and those without mutations in either of these genesCrossRef
36.
Jacobs IJ, Skates SJ, MacDonald N, et al: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999, 353: 1207-1210. 10.1016/S0140-6736(98)10261-1.CrossRefPubMed
37.
McWhorter WP, Hernandez AO, Meikle AW, et al: A screening study of prostate cancer in high risk families. J Urol . 1992, 148: 826-828.PubMed
38.
Lynch HT, Watson P, Lanspa SJ, et al: Natural history of colorectal cancer in hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). Dis Colon Rectum. 1988, 31: 439-444.CrossRefPubMed
39.
Brunet JS, Ghadirian P, Rebeck TR, et al: Effect of smoking on breast cancer in carriers of mutant BRCA 1 or BRCA 2 genes. J Natl Cancer Inst. 1998, 90: 761-765. 10.1093/jnci/90.10.761.CrossRefPubMed
40.
Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA: Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr. 1995, 17: 33-35., This reference shows that prophylactic oophorectomy reduces ovarian cancer risk
41.
Rebbeck T, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA 1 mutation carriers. J Natl Cancer Inst. 1999, 91: 1475-1479. 10.1093/jnci/91.17.1475., This reference shows that prophylactic oophorectomy reduces both ovarian and breast cancer risk in BRCA carriersCrossRefPubMed
42.
Jernström H, Lerman C, Ghadirian P, et al: Pregnancy and risk of early breast cancer in carriers of BRCA 1 and BRCA2. Lancet. 1999, 354: 1846-1850. 10.1016/S0140-6736(99)04336-6.CrossRefPubMed
43.
Cuzick J: Future possibilities in the prevention of breast cancer: breast cancer prevention trials. Breast Cancer Res. 2000,
44.
Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371., See [46]CrossRefPubMed
45.
Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998, 352: 98-101., See [46]CrossRefPubMed
46.
Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998, 352: 93-97., These three papers [44–46] describe three trials that investigate the role of Tamoxifen as a chemopreventive agent for breast cancerCrossRefPubMed
47.
Lerman C, Narod S, Schulman K, et al: BRCA 1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA. 1996, 275: 1885-1892. 10.1001/jama.275.24.1885.CrossRefPubMed
48.
49.
Meijers-Heijboer H, Verhoog L, Brekelmans C, et al: Prophylactic surgery in BRCA 1/2 mutation carriers: predictive factors and follow-up [abstract]. Am J Hum Genet. 1999, 65: 111-10.1086/302455.CrossRef
50.
Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999, 340: 77-84. 10.1056/NEJM199901143400201., This is the most commonly quoted reference to support the suggestion that prophylactic mastectomy reduces risk of breast cancer. The problem is that this study, of necessity, was retrospective and many women did not have genetic analysis performedCrossRefPubMed
51.
Daltrey IR, Eeles RA, Kissin MW: Bilateral prophylactic mastectomy: not just a woman's problem!. Breast. 1998, 7: 236-237. 10.1016/S0960-9776(98)90118-7.CrossRef
52.
Stefanek M, Enger C, Benkendorf J, Flamm-Honig S, Lerman C: Bilateral prophylactic mastectomy decision making: a vignette study. Prev Med. 1999, 29: 216-221. 10.1006/pmed.1999.0524.CrossRefPubMed
53.
Brinton LA, Brown SL: Breast implants and cancer. J Natl Cancer Inst. 1997, 89: 1341-1349. 10.1093/jnci/89.18.1341.CrossRefPubMed
54.
Piver MS, Jishi MF, Tsukada Y, Nava G: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian carcinoma. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 1993, 71: 2751-55.CrossRefPubMed
55.
Breast Cancer Linkage Consortium: The pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997, 349: 1505-1510. 10.1016/S0140-6736(96)10109-4.CrossRef
56.
Chappuis PO, Rosenblatt J, Foulkes WD: The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol. 1999, 10: 1163-1170. 10.1023/A:1008301314812., This reference summarizes the studies investigating survival differences in women who have breast cancer who are BRCA1/BRCA2 carriers versus sporadic casesCrossRefPubMed
57.
Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA 1. Lancet. 1998, 351: 316-321. 10.1016/S0140-6736(97)07065-7.CrossRefPubMed
58.
Foulkes WD, Wong N, Brunet JS, et al: Germ-line BRCA 1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res. 1997, 3: 2465-2469.PubMed
59.
Lee JS, Wacholder S, Struewing JP, et al: Survival after breast cancer in Ashkenazi Jewish BRCA 1 and BRCA2 mutation carriers. J Natl Cancer Inst. 1999, 91: 259-263. 10.1093/jnci/91.3.259.CrossRefPubMed
60.
Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival in hereditary breast cancer associated with germline mutations of BRCA 2. J Clin Oncol. 1999, 17: 3396-3402.PubMed
61.
Early Breast Cancer Trialists' Collaborative Group : Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992, 339: 71-85. 10.1016/0140-6736(92)90997-H.
62.
Robson M, Gilewski T, Haas B, et al: BRCA -associated breast cancer in young women. J Clin Oncol. 1998, 16: 1642-1649.PubMed
63.
Cannistra SA: BRCA1 mutations and survival in women with ovarian cancer [letter]. N Engl J Med. 1997, 336: 1254; discussion 1256-1257. 10.1056/NEJM199704243361713.
64.
Johannsson O, Ranstam J, Borg A, Olsson H: BRCA 1 mutations and survival in women with ovarian cancer. N Engl J Med. 1997, 336: 1255-1256; discussion 1256-1257.
65.
Whitmore SE: BRCA1 mutations and survival in women with ovarian cancer [letter]. N Engl J Med. 1997, 336: 1254-1255; discussion 1256-1257.
66.
Modan B: BRCA 1 mutations and survival in women with ovarian cancer [letter]. N Engl J Med. 1997, 336: 1255; discussion 1256-1257.
67.
Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA: Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res. 1999, 59: 868-871.PubMed
68.
Shen SX, Weaver Z, Xu X, Li C, Weinstein M, Chen L, et al: A targeted disruption of the murine brca 1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene. 1998, 17: 3115-3124. 10.1038/sj.onc.1202243.CrossRefPubMed
69.
Sharan SK, Morimatsu M, Albreicht U, et al: Embyronic lethality and radiation hypersensitivity mediated by Rad 51 in mice lacking brca 2. Nature. 1997, 386: 804-810. 10.1038/386804a0.CrossRefPubMed
70.
Coleman CN: Molecular biology in radiation oncology. Radiation oncology perspective of BRCA 1 and BRCA2. Acta Oncol. 1999, 38 (Suppl 13): 55-59. 10.1080/028418699432770.CrossRef
71.
Early Breast Cancer Trialists' Collaborative Group : Ovarian oblation in early breast cancer: overview of the randomised trials. Lancet. 1996, 348: 1189-1196. 10.1016/S0140-6736(96)05023-4.CrossRef
72.
Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998, 16: 2417-2425.PubMed
Metadata
Title
Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
Author
Rosalind A Eeles
Publication date
01-08-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr70

Other articles of this Issue 4/2000

Breast Cancer Research 4/2000 Go to the issue

Research article

BRCA1 and BRCA2 mutations in central and southern Italian patients

Research article

Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE

Commentary

New hurdles for translational research

Meeting report

91st Annual Meeting of the American Association for Cancer Research

Non-peer-reviewed research

Differential Expression of Mammastatin in Normal and Breast Cancer Cells

Commentary

Acetyltransferases and tumour suppression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits